

July 23, 2020

Listing Department

Code: 532 321

**BSE LIMITED**

P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

Listing Department

Code: CADILAHC

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400 051

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated July 23, 2020 titled “Zydus receives approval from USFDA to initiate clinical trials of Desidustat in cancer patients receiving chemotherapy”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



**DHAVAL N. SONI**  
**COMPANY SECRETARY**



Encl.: As above

## Zydu receives approval from USFDA to initiate clinical trials of Desidustat in cancer patients receiving chemotherapy

- *Approximately 1.3 million cancer patients are estimated to be undergoing chemotherapy every year in the US and ~ 30% to 90% of cancer patients receiving chemotherapy, develop anemia*
- *Desidustat, is currently undergoing Phase III clinical development for treating Anemia in CKD patients; and Phase II(b) studies for management of COVID-19 patients*

Ahmedabad, India, July 23, 2020

Zydu, a leading discovery based, global pharmaceutical company today announced that it has received approval from the USFDA, to initiate clinical trials of Desidustat in Chemotherapy Induced Anemia (CIA).

Cancer Patients undergoing chemotherapy develop anemia. CIA results in fatigue, impaired quality of life, discontinuation of chemotherapy and also exposes these cancer patients to red-blood cell transfusions. Desidustat is expected to increase the red blood cell count and restore the erythropoietin levels to the normal levels in the cancer patients with CIA. Estimates suggest approximately 1.3 million cancer patients undergo chemotherapy every year in the United States and 30% to 90% of cancer patients receiving chemotherapy develop anemia

Speaking on the development, Pankaj R. Patel, Chairman, Zydu Cadila said, “Chemotherapy-Induced Anemia or CIA is a serious unmet medical need and there is a need for novel therapies to address this condition. Desidustat has been specifically designed to improve haemoglobin, reduce hepcidin and thereby treat anemia. We are committed to develop Desidustat and support cancer patients battling Chemotherapy Induced Anemia.”

Desidustat is a novel, oral, hypoxia inducible factor prolyl hydroxylase inhibitor, currently undergoing Phase 3 trials for treating anemia in Chronic Kidney Disease Patients. Zydu had initiated two Phase III trials of Desidustat. The DREAM-ND Phase III trial is being conducted in 588 CKD patients not-on-dialysis [ClinicalTrials.gov Identifier: NCT04012957]. The DREAM-D Phase III trial is being conducted in 392 CKD patients on Dialysis [ClinicalTrials.gov Identifier: NCT04215120]. Desidustat had previously met its primary endpoints in the Phase II clinical studies and showed good safety profile. The Phase I trials were earlier completed in Australia.

Zydu has also initiated a Phase II(b) trial of Desidustat in Mexico for the management of patients with COVID-19. [ClinicalTrials.gov Identifier: NCT04463602].



Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

## About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs nearly 25,000 people worldwide, including 1,400 scientists engaged in R & D, and is dedicated to creating healthier communities globally. [www.zyduscadila.com](http://www.zyduscadila.com)

For further information please contact :  
**The Corporate Communications Department**

### **Cadila Healthcare Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.

Phone : +91-079-71800000, +91-079-48040000 [www.zyduscadila.com](http://www.zyduscadila.com)

CIN : L24230GJ1995PLC025878